Corcept Therapeutics Inc. (CORT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Key Insights
Critical company metrics and information
Share Price
$59.26Market Cap
$6.21 BillionTotal Outstanding Shares
104.78 Million SharesTotal Employees
352Dividend
No dividendIPO Date
April 14, 2004SIC Description
Pharmaceutical PreparationsHomepage
https://www.corcept.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $25.49 Million |
Net Cash Flow From Operating Activities, Continuing | $144.65 Million |
Net Cash Flow | $25.49 Million |
Net Cash Flow From Investing Activities, Continuing | $-96.15 Million |
Net Cash Flow From Financing Activities, Continuing | $-23.02 Million |
Net Cash Flow From Financing Activities | $-23.02 Million |
Net Cash Flow From Operating Activities | $144.65 Million |
Net Cash Flow From Investing Activities | $-96.15 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $24.52 Million |
Basic Average Shares | $308.91 Million |
Basic Earnings Per Share | $1.36 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $735,000.00 |
Gross Profit | $618.75 Million |
Net Income/Loss Attributable To Parent | $141.82 Million |
Costs And Expenses | $485.20 Million |
Net Income/Loss | $141.82 Million |
Cost Of Revenue | $9.80 Million |
Diluted Average Shares | $334.57 Million |
Income/Loss From Continuing Operations Before Tax | $166.34 Million |
Operating Income/Loss | $143.36 Million |
Benefits Costs and Expenses | $462.21 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Earnings Per Share | $1.26 |
Revenues | $628.55 Million |
Net Income/Loss Available To Common Stockholders, Basic | $140.47 Million |
Research and Development | $231.29 Million |
Preferred Stock Dividends And Other Adjustments | $735,000.00 |
Nonoperating Income/Loss | $22.98 Million |
Income Tax Expense/Benefit, Deferred | $-40.01 Million |
Selling, General, and Administrative Expenses | $244.10 Million |
Income/Loss From Continuing Operations After Tax | $141.82 Million |
Operating Expenses | $475.39 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $126.22 Million |
Inventory | $8.05 Million |
Noncurrent Liabilities | $19.21 Million |
Noncurrent Assets | $317.28 Million |
Current Assets | $466.98 Million |
Liabilities | $145.42 Million |
Other Non-current Assets | $314.35 Million |
Other Current Assets | $453.11 Million |
Accounts Payable | $18.58 Million |
Equity Attributable To Parent | $638.84 Million |
Liabilities And Equity | $784.26 Million |
Equity | $638.84 Million |
Prepaid Expenses | $5.82 Million |
Assets | $784.26 Million |
Fixed Assets | $2.93 Million |
Other Current Liabilities | $107.63 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.